Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells》.pdfVIP

Lung Cancer 82 (2013) 397–406 Contents lists available at ScienceDirect Lung Cancer j o u r na l h o me p a ge : w w w. elsev /locate / l un g can Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells Jen-Chung Ko a,b,c , Hsien-Chun Chiu d , Ting-Yu Wo d,1, Yi-Jhen Huang d,1, Sheng-Chieh Tseng d , Yu-Ching Huang d , Huang-Jen Chen d , Jhan-Jhang Syu d , Chien-Yu Chen d , Yun-Ting Jian d , Yi-Jun Jian d , Yun-Wei Lin d,∗ a Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Taiwan b Department of Nursing, Yuanpei University, Hsinchu, Taiwan c Institute of Technology Law, National Chiao Tung University, Hsinchu, Taiwan d Molecular Oncology Laboratory, Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan a r t i c l e i n f o a b s t r a c t Article history: Objectives: Gefitinib, a quinazoline-derived tyrosine kinase inhibitor, has anti-tumor activity in vivo and Received 20 May 2013 in vitro. Human MutS homologue-2 (MSH2) plays a central role in promoting genetic stability by correct- Received in revised form ing DNA replication errors. The present study investigated the effects of p38 mitogen-activated protein 12 September 2013 kinase (MAPK) signal on gefitinib-induced MSH2 expression in two human non-small cell lung squamous Accepted 18 September 2013 cancer cell lines.